Share this article on:

Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function

German, Polina PharmD; Liu, Hui C. PhD; Szwarcberg, Javier MD; Hepner, Mischa BS; Andrews, Jessica MSPH; Kearney, Brian P. PharmD; Mathias, Anita PhD

JAIDS Journal of Acquired Immune Deficiency Syndromes: September 1st, 2012 - Volume 61 - Issue 1 - p 32–40
doi: 10.1097/QAI.0b013e3182645648
Clinical Science

Objective: This study evaluated the effect of cobicistat (COBI) on glomerular filtration rate in subjects with normal renal function (RF) or with mild/moderate renal impairment, by comparing creatinine clearance [estimated glomerular filtration rate (eGFR)] with actual GFR (aGFR) using iohexol, a probe drug excreted by glomerular filtration. COBI is a potent CYP3A inhibitor (pharmacoenhancer) currently in phase 3 testing with elvitegravir, atazanavir, and darunavir.

Methods: Normal RF subjects received COBI 150 mg QD, ritonavir (RTV) 100 mg QD, or placebo for 7 days; subjects with mild/moderate renal impairment received COBI 150 mg QD. The eGFR and aGFR were measured on days 0, 7, and 14 and within-subject changes calculated relative to day 0. COBI and RTV pharmacokinetics were analyzed on day 7.

Results: All 36 subjects in cohort 1 and 17 of 18 subjects in cohort 2 completed all study treatments. Study treatments were well tolerated. Small increases in serum creatinine with corresponding mean decreases in eGFR (∼10 mL/min or mL/min per 1.73 m2) were observed on day 7 relative to day 0 in subjects receiving COBI (P < 0.05). The decreases were reversible on COBI discontinuation; mean eGFR values returned to baseline on day 14 (P > 0.05). No statistically significant changes in aGFR on days 7 or 14 relative to day 0 were seen with COBI (P > 0.05). No statistically significant decreases in aGFR or eGFR were observed with RTV or placebo.

Conclusions: COBI affects eGFR but not the actual GFR. The time to onset, magnitude, and time to resolution of changes in eGFR are consistent with altered proximal tubular secretion of creatinine through inhibition of drug transporters.

Gilead Sciences, Inc, Foster City, CA.

Correspondence to: Polina German, PharmD, Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404 (e-mail: polina.german@gilead.com).

Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17–20, 2011, Chicago, IL (abstract number H2-804/294 plus poster).

The authors are employees of Gilead Sciences, Inc. Gilead Sciences employees potentially own stock and/or hold stock options in the company.

Received March 15, 2012

Accepted June 12, 2012

© 2012 Lippincott Williams & Wilkins, Inc.